ELAHERE ® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

ELAHERE ® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients#ELAHERE #mirvetuximab #soravtansinegynx #Shows #Consistent #Survival #Benefit #LongTerm #Analysis #Ovarian #Cancer #Patients